A recombinant human EGF protein is produced by a technique called recombinase. The biological activities of EGF are highly relevant to the human body. Researchers measure these activities using human-derived normal skin cells. The EGF tertiary structure is unique and changes when the protein is treated with heat. Moreover, it can lose its biological activity if it is modified. For this reason, it is necessary to use a purified form of the protein. This way, researchers can monitor the stability of the EGF protein.
Recombinant human EGF has a remarkable effect on the differentiation of specific cells in vivo and in vitro. It is thought to be a membrane-bound molecule that cleaves to produce a 53-amino acid peptide hormone that stimulates cell division. In vitro, human epidermal cells and certain fibroblasts are stimulated by the substance. Its production is a highly controlled process involving E. coli and other bacterial strains.
Recombinant human EGF protein is a highly versatile protein used in diagnostics and target therapeutics. The quality of this protein is extremely high. It is also stable to heat. Therefore, the protein can be used for many applications, including clinical trials and drug development. It can be used in clinical trials, animal experiments, and drug development. The price is low compared to other protein reagents.
As per market survey by Coherent Market Insights,Recombinant Human EGF Market to Surpass US$ 19,103.4 Million by 2028
A study in guinea pigs found that blocking EGFR and EGF prevented lens-induced myopia. Interestingly, the antibody reduced the axial elongation of the lens in guinea pigs. In addition, it increased the thickness of the retina at the posterior pole. These results suggest that recombinant human EGF protein is a useful therapeutic tool in ophthalmology.
Mutants of recombinant human EGF in the zebrafish intestine have decreased ubiquitination. EGFR has been reported to be an ubiquitin-ligase substrate for ZNRF1. It is thought that CBL inhibits the ubiquitination of EGFR. Nonetheless, further studies are necessary to confirm whether or not EGFR promotes ubiquitination in mutants. For instance, in December 2021, Takara Bio, Inc., a major biotechnology firm in Japan, synthesized the complementary DNA (cDNA) template with PrimeScript RT Master to investigate the potential key genes related to CRSwNP (Chronic rhinosinusitis with nasal polyps).
ERRP inhibits the phosphorylation of EGFR in epidermal growth factor-induced gastric cancer cells. EGFR is a crucial molecule in gastric cancer cell activation. Exogenous ERRP inhibits phosphorylation of EGFR in hepatocytes and gastric cancer cells. These data suggest that recombinant human EGF protein may represent a new therapeutic target for gastric cancer treatment.
